Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study
Authors
Keywords
-
Journal
BMC Nephrology
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2012-11-20
DOI
10.1186/1471-2369-13-150
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease
- (2013) Regina Kunz et al. ANNALS OF INTERNAL MEDICINE
- Efficacy and Safety of Paricalcitol Therapy for Chronic Kidney Disease: A Meta-Analysis
- (2012) J. Cheng et al. Clinical Journal of the American Society of Nephrology
- Antiproteinuric Response to Add-on Aliskiren in Proteinuric Patients Treated With Dual Blockade of the Renin-Angiotensin System: A 12-Month Prospective Uncontrolled Study
- (2011) Luca De Nicola et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Oral Calcitriol for Reduction of Proteinuria in Patients With IgA Nephropathy: A Randomized Controlled Trial
- (2011) Li-Jun Liu et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Prognosis of CKD Patients Receiving Outpatient Nephrology Care in Italy
- (2011) L. De Nicola et al. Clinical Journal of the American Society of Nephrology
- Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin–angiotensin–aldosterone system inhibition
- (2011) Min Jeong Kim et al. KIDNEY INTERNATIONAL
- Intensive Versus Conventional Therapy to Slow the Progression of Idiopathic Glomerular Diseases
- (2010) Stefano Bianchi et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects?
- (2010) Rajiv Agarwal KIDNEY INTERNATIONAL
- Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes
- (2010) Dilip K. Deb et al. KIDNEY INTERNATIONAL
- Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
- (2010) Dick de Zeeuw et al. LANCET
- Oral Paricalcitol in the Treatment of Patients With CKD and Proteinuria: A Randomized Trial
- (2009) Steven Fishbane et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Proteinuria as a Surrogate Outcome in CKD: Report of a Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration
- (2009) Andrew S. Levey et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Renoprotective effects of vitamin D analogs
- (2009) Yan Chun Li KIDNEY INTERNATIONAL
- Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney Disease
- (2008) Pooneh Alborzi et al. HYPERTENSION
- Paricalcitol Inhibits Renal Inflammation by Promoting Vitamin D Receptor-Mediated Sequestration of NF- B Signaling
- (2008) X. Tan et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Role of Remission Clinics in the Longitudinal Treatment of CKD
- (2008) P. Ruggenenti et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase
- (2008) Z. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The importance of the intrarenal renin–angiotensin system
- (2008) Juan Carlos Q Velez Nature clinical practice. Nephrology
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started